P lasma endothelin-1 (ET-1) levels are elevated in patients with heart failure 1 and have prognostic significance. 2 ET-1 levels correlate strongly with pulmonary artery pressures and pulmonary vascular resistance (PVR), 1, 3 which suggests that ET-1 may be a mediator of reactive pulmonary hypertension in the setting of left ventricular (LV) failure. The actions of ET-1 are mediated by 2 receptor subtypes, designated ET A and ET B . ET A receptors located on vascular smooth muscle cells mediate vasoconstriction. 4 ET B receptors located primarily on vascular endothelial cells mediate NOdependent vasodilation, 5 although some ET B receptors located on vascular smooth muscle cells may mediate vasoconstriction. 6 ET B receptors also play a role in ET-1 clearance. 7 Understanding of the actions of ET-1 in heart failure has been aided by the development of ET receptor antagonists. Acute intravenous 8 and short-term oral 9 administration of bosentan, a nonselective (ET A /ET B ) receptor antagonist, caused systemic and pulmonary vasodilation in patients with severe heart failure. Because ET B receptors are coupled to endothelium-dependent vasodilation, it might be anticipated that ET A -selective antagonists would be more effective vasodilators than nonselective antagonists. However, there has been relatively little experience with ET A -selective antagonists in patients with heart failure, save for a small, uncontrolled study of the intravenous administration of the ET Aselective antagonist BQ-123. 10 Sitaxsentan is a nonpeptide, small organic molecule that binds competitively to the human ET A receptor with high affinity (K I ϭ0.43 nmol/L). Sitaxsentan is 6000-fold more selective for the human ET A receptor than for the human ET B receptor. 11 Preclinical studies have shown that sitaxsentan exerts potent vasodilator effects. In rats with hypoxia-induced pulmonary hypertension, sitaxsentan attenuated the increase in pulmonary artery pressure but had no effect on heart rate (HR) or mean arterial pressure (MAP) (Tommy Brock, PhD, unpublished data, 1997). These preliminary data suggest that sitaxsentan may exert a specific action on the pulmonary circulation. We undertook a double-blind, placebo-controlled, randomized study with sitaxsentan to determine the acute hemodynamic effects of ET A receptor blockade in patients with stable chronic heart failure.
Methods

Study Population
The study population consisted of 48 adults, aged Ն21 years, with chronic New York Heart Association (NYHA) class III or IV heart failure and an LV ejection fraction Յ35%. All patients were receiving a diuretic and ACE inhibitor (or had failed attempts to start an ACE inhibitor). Digoxin, amlodipine or nifedipine, and metoprolol or carvedilol were allowed. All patients had a baseline pulmonary capillary wedge pressure (PCWP) Ն15 mm Hg and a cardiac index (CI) Յ2.5 L ⅐ min Ϫ1 ⅐ m Ϫ2 . Exclusion criteria included myocardial infarction within 8 weeks; unstable angina or angina-limited exercise; heart failure due to uncorrected valvular stenosis, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis, or a malfunctioning artificial heart valve; symptomatic chronic obstructive pulmonary disease or asthma; history of symptomatic ventricular tachycardia, ventricular fibrillation, or sudden death unless treated with an implantable defibrillator; history of second-or third-degree A-V block unless treated with a pacemaker; HR Ͼ115 bpm; and systolic blood pressure Ͻ90 mm Hg or Ͼ200 mm Hg. The study protocol was approved by the institutional review committee at each study site, and all patients provided written informed consent.
Randomization and Blinding
A single computer-generated randomization code was used for all sites and was coordinated by an independent randomization center. The first 24 patients were randomized in a 1:1:1 ratio to 1 of 3 treatment groups: sitaxsentan 1.5 mg/kg (dose level 1), sitaxsentan 3.0 mg/kg (dose level 2), or placebo (5% dextrose in water). Based on the safety results of the first 24 subjects enrolled and an interim analysis of the pharmacodynamic effects of the 1.5 and 3.0 mg/kg doses, the protocol was amended to eliminate dose level 1 and add a third dose of sitaxsentan (6.0 mg/kg; dose level 3). The subsequent 24 patients were randomized in a 1:1:1 ratio to: sitaxsentan 3.0 mg/kg, sitaxsentan 6.0 mg/kg, or placebo. Study drug was prepared by a research pharmacist and infused in a blinded fashion over 15 minutes into a peripheral vein by site personnel who were not associated with the subject's clinical management.
Hemodynamic Measurements
After insertion of a Swan-Ganz catheter and after Ն1 hour of stabilization, 2 sets of baseline hemodynamic measurements were obtained. When CI and PCWP values differing by Ͻ15% were obtained on subsequent measurements, the study drug was infused over 15 minutes, and the following hemodynamic measurements were obtained at 15 and 30 minutes and at 1, 2, 3, 4, and 6 hours after completion of drug infusion: HR, systemic arterial pressure (systolic and diastolic), pulmonary arterial pressure (mean systolic and diastolic), PCWP, cardiac output (by thermodilution or Fick method), and mean right atrial pressure (RAP). Mean systemic arterial pressure, systemic vascular resistance (SVR), PVR, CI, and LV stroke work index were derived according to standard formulas.
Concomitant Medications
All medications with possible hemodynamic effects, including vasodilators, ACE inhibitors, ␤-blockers, calcium channel blockers, diuretics, digoxin, and antiarrhythmics, were withheld beginning at midnight on the day of the study and throughout the 6-hour blinded evaluation period. Sitaxsentan sodium (Texas Biotechnology Corporation) was supplied as 250 mg of a sterile, yellow lyophilized cake in a clear 20-mL vial. Sitaxsentan was reconstituted with 10 or 20 mL of sterile water to yield a final concentration of 25 or 12.5 mg/mL, respectively, and the infusion dose was calculated based on the patient's weight and randomized dose level. Patients were limited to light liquid meals no less than 1 hour before baseline measurements and after hemodynamic readings were obtained at hour 4.
Laboratory Analyses
Blood was obtained for general chemistry, complete blood count with differential, and international normalized ratio (INR) at baseline and after completion of the study. Plasma ET-1, norepinephrine, and tumor necrosis factor-␣ (TNF-␣) levels were determined from blood drawn at baseline and at 3 and 6 hours after study-drug infusion. ET-1 levels were measured by radioimmunoassay with a commercial kit (Phoenix Pharmaceuticals). TNF-␣ levels were measured by ELISA with a commercial kit (R&D Systems). Norepinephrine levels were measured by high-performance liquid chromatography with electrochemical detection. 
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Statistical Analysis
To determine the comparability of the 4 treatment groups for demographic and baseline variables, categorical variables were analyzed via Fisher's exact test and continuous variables by 1-way ANOVA with effects for treatment. Primary efficacy analyses were performed on all enrolled patients according to intention to treat, and missing data were replaced by the last-observation-carried-forward principle. For each time point, differences among the treatment groups in mean change from baseline were determined via 1-way ANOVA with effects for treatment. In addition, a repeated-measures model was used on the changes from baseline to determine the effects of treatment, time, and the interaction of treatment and time. Safety was assessed by comparing the treatments with respect to the occurrence of adverse experiences and the changes from baseline in laboratory values and ECG measurements. All analyses were performed with the SAS statistical package (SAS Institute), and data are presented as meanϮSEM, with a value of PϽ0.05 considered statistically significant.
Results
Patient Characteristics
There were no significant differences among the treatment groups with respect to age, sex, LV ejection fraction, NYHA class, or resting hemodynamics (Table 1) . Eighty-three percent of patients were male, and 77% were in NYHA functional class III. The majority of patients were taking an ACE inhibitor (92%), diuretic (96%), and digoxin (88%). Resting hemodynamics revealed moderate-to-severe heart failure with elevated right-and left-heart filling pressures, reduced CI, and increased SVR. Pulmonary hypertension was present with a mean pulmonary artery systolic pressure (PASP) of 60Ϯ2 mm Hg and a mean PVR of 349Ϯ33 dyne ⅐ s ⅐ cm
Ϫ5
.
Hemodynamic Effects of Sitaxsentan
The hemodynamic effects of sitaxsentan are shown in Table  2 . Table 3 summarizes the overall treatment effect of sitaxsentan on hemodynamic parameters as analyzed by intention to treat across all doses (versus placebo). Compared with placebo, sitaxsentan caused significant reductions in PASP, PVR, mean pulmonary artery pressure (MPAP), and RAP (PՅ0.001, 0.003, 0.017, and 0.031, respectively) ( Figure 1 ). The decrease in PASP was significant by 30 minutes, maximal at 2 to 3 hours, and persisted for Ն6 hours after the infusion ( Figure 1A ). The decrease in PASP was similar at all 3 doses tested. At 2 hours, PASP decreased by 13%, 10%, and 11% in the sitaxsentan 1.5-, 3.0-, and 6.0-mg/kg groups, respectively, and increased by 4% in the placebo group. Likewise, at 2 hours, PVR decreased by 38%, 34%, and 20% in the sitaxsentan 1.5-, 3.0-, and 6.0-mg/kg groups, respectively, and increased by 20% in the placebo group ( Figure  1B) . In patients receiving sitaxsentan, baseline PVR predicted the magnitude of the decrease in PVR at 2 hours (Figure 2) . At 2 hours, RAP decreased by 13%, 23%, and 17% in the sitaxsentan 1.5-, 3.0-, and 6.0-mg/kg groups, respectively, and increased by 11% in the placebo group.
In contrast to the effects on pulmonary and right-heart hemodynamics, sitaxsentan exerted no discernible effect on HR, MAP, PCWP, or SVR (Tables 2 and 3 ). There were weak trends for CI to increase (Pϭ0.202) and MAP to decrease (Pϭ0.258).
Plasma ET-1, Norepinephrine, and TNF-␣ Levels
In the study population as a whole, baseline ET-1 levels were markedly elevated, with a mean value of 15.4Ϯ1.5 pg/mL. There were no between-group differences. Baseline ET-1 levels did not correlate with baseline PVR (rϭ0.05, Pϭ0.75) or the reduction in PVR (2 hours) with sitaxsentan (rϭ0. 26, Pϭ0.19) . Of note, plasma ET-1 levels decreased by 18Ϯ8% and 21Ϯ8% at 3 and 6 hours, respectively, in patients receiving sitaxsentan but did not change in the placebo group (Figure 3 ). Plasma norepinephrine (680Ϯ49 pg/mL) and TNF-␣ (3.3Ϯ0.3 pg/mL) levels were elevated at baseline but did not change in any of the treatment groups (data not shown).
Adverse Effects
Overall, 46% of all patients experienced an adverse event (Table 4 ). However, except for an increase in the frequency of gastrointestinal events reported with sitaxsentan (2 in the 6.0-mg/kg dose group; Pϭ0.05), there were no significant differences among treatment groups with respect to adverse events, including congestive heart failure, hypotension, bradycardia, and ventricular arrhythmias. Sitaxsentan had no effect on the complete blood count, serum blood urea nitrogen or creatinine, liver-function tests, or INR over the 6-hour study period. 
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Discussion
The major new finding of this study is that acute infusion of the ET A -selective antagonist sitaxsentan decreased PVR in patients with chronic stable heart failure but exerted little or no effect on systemic vascular tone. This selective pulmonary vasodilator action was apparent within 30 minutes, persisted for Ն6 hours after drug infusion, and was maximal at the lowest dose tested. Of note, the hemodynamic effect of sitaxsentan was associated with a decrease in plasma ET-1 levels. This pattern of hemodynamic effect appears to differ from that observed with acute administration of the nonselective ET A /ET B receptor antagonist bosentan. Kiowksi et al 8 randomized 24 patients with NYHA class III heart failure to receive bosentan or placebo by intravenous infusion. Bosentan decreased MAP, MPAP, PCWP, PVR, and SVR and increased CI. Similar hemodynamic effects were seen after 2 weeks of oral bosentan therapy. 9 Cowburn et al 10 infused the ET A -selective antagonist BQ-123 for 60 minutes in 8 patients with stable chronic heart failure. In that uncontrolled study, BQ-123 caused modest decreases in SVR (12%) and PVR (14%), and a small increase in CI.
It is possible that the differing hemodynamic effects of sitaxsentan and bosentan reflect their differences in receptor selectivity. It is also possible that they are due to an inherent difference in the study populations or protocols. Regardless of the reason, it can be concluded that under the conditions of the present study, acute infusion of sitaxsentan exerted a selective pulmonary vasodilator effect. Such an action is consistent with the demonstration that ET-1 causes concentration-dependent contraction of pulmonary arteries and veins in vitro 12 and increases PVR in vivo. 13 Both of these actions are mediated predominantly by the ET A receptor. 14 Stimulation of ET B receptors in the pulmonary vasculature generally attenuates ET A -mediated vasoconstriction, 15 although pulmonary vasoconstrictor effects have also been reported. 16 The extent to which sitaxsentan decreased PVR was strongly correlated with the baseline PVR. This observation may explain the lack of a significant pulmonary vasodilator effect with BQ-123, because in the study by Cowburn et al, 10 patients had only mild pulmonary hypertension with a mean PVR of Ϸ180 dyne ⅐ s ⅐ cm
Ϫ5
. By contrast, our patients had moderate-to-severe pulmonary hypertension with a mean PVR of 349 dyne ⅐ s ⅐ cm
. In patients with heart failure, inhaled NO also exerts a selective pulmonary vasodilator action, apparently owing to its route of administration. 17 Interestingly, we found that the pulmonary vasodilator effect of inhaled NO also correlated best with the baseline PVR. 17 However, in contrast to inhaled NO, sitaxsentan did not cause an increase in PCWP.
It is surprising that sitaxsentan did not decrease SVR. Infusion of another ET A -selective antagonist, BQ-123, into the brachial artery of patients with heart failure caused vasodilation. 18 Although it is possible that higher doses of sitaxsentan would have decreased SVR, the pulmonary vasodilator effects that we observed appeared to be maximal at the lowest dose tested and, if anything, may have diminished at higher doses. One possible explanation for these findings is that a component of the elevated SVR in patients with heart failure is due to vasoconstrictor ET B receptors located on systemic resistance vessels. In support of this thesis, the intra-arterial infusion of sarafotoxin S6c, an ET B receptor agonist, causes an enhanced vasoconstrictor response in patients with heart failure. 18 Likewise, intravenous infusion of the selective ET B receptor agonist ET-3 resulted in constriction of systemic but not pulmonary vasculature in patients with LV failure. 19 An enhanced vasoconstrictor response to ET B stimulation in heart failure might reflect desensitization of ET A receptors in the systemic vasculature. 20 Despite a reduction in PVR, sitaxsentan did not significantly increase CI. There are several possible explanations. As mentioned, we did not observe a decrease in SVR, and in the absence of a positive inotropic effect, sitaxsentan would not be expected to increase CI. Second, we did not observe an increase in LV preload. Indeed, even if PCWP had increased with sitaxsentan, we might not have observed an increase in CI with selective pulmonary vasodilation. In a prior study using the selective pulmonary vasodilator inhaled NO, we demonstrated small but significant decreases in CI and stroke volume index associated with a 23% increase in PCWP. 17 Another potential explanation for the lack of increase in CI is that sitaxsentan exerted a negative inotropic effect. ET A receptors are expressed in human myocardium 21 and mediate the positive inotropic effect of ET-1. 22 Consistent with previous reports, 1 we found increased plasma ET-1 levels in patients with moderate-to-severe heart failure. However, baseline ET-1 levels did not correlate with pulmonary artery pressures or PVR, or with the change in PVR after ET A blockade. In prior studies 8, 9 with the nonselective ET receptor antagonist bosentan, ET-1 levels increased within 2 to 3 hours of administration. The increase in plasma ET-1 with bosentan is thought to be due to displacement of ET-1 from receptor binding sites and/or decreased clearance by ET B receptors. 7 In striking contrast, sitaxsentan caused a decrease in ET-1 levels. The mechanism for this decrease in plasma ET-1 is not clear. Given the important role of the pulmonary vasculature in contributing ET-1 to the systemic circulation, it is possible that it reflects reduced ET-1 pulmonary vascular production due to improved pulmonary hemodynamics. Another possibility is that selective Values are n (%). *Pϭ0.05.
